Navidea, Cardinal Health deal

Navidea will sell its Lymphoseek tilmanocept imaging agent to Cardinal Health for oncology indications

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE